EUVIMEDEUVIMED entdecken
Crossref

Experimental therapies in Irritable Bowel Syndrome

Folia Medica Cracoviensia · 2023

DOI: 10.24425/fmc.2021.137209 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Folia Medica Cracoviensia, 2023.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Irritable bowel syndrome (IBS) is a multifactorial gastrointestinal disorder with still not fully understood pathogenesis.At first, the treatment of IBS was mainly focused on alleviating symptoms (with the use of laxatives, anti-diarrheals, anti-spasmodics and painkillers) and then became more specific by targeting discovered pathways responsible for proper functioning of the gastrointestinal system, for instance: 5HT3, 5HT4, cannabinoid and opioid receptors, guanylyl cyclase C, chloride channels and sodiumhydrogen exchanger.Nowadays, there is a growing number of experimental IBS treatment strategies and in this article we discuss these novel and therapeutic options in IBS, their efficacy and future perspectives.

Zitieren

APA

(2023). Experimental therapies in Irritable Bowel Syndrome. Folia Medica Cracoviensia. https://doi.org/10.24425/fmc.2021.137209

Vancouver

Experimental therapies in Irritable Bowel Syndrome. Folia Medica Cracoviensia. 2023. doi:10.24425/fmc.2021.137209

BibTeX
@article{euvimed2023,
  title = {Experimental therapies in Irritable Bowel Syndrome},
  journal = {Folia Medica Cracoviensia},
  year = {2023},
  doi = {10.24425/fmc.2021.137209}
}
Kostenlos starten →